[Thrombolytic (fibrinolytic) agents for treatment of ischemic heart disease].
Nagao
Ken
K
Department of Emergency and Critical Care Medicine, Nihon University School of Medicine.
Kanmatsuse
Katsuo
K
D002543:Cerebral Hemorrhage / Q000139:chemically induced; D003326:Coronary Circulation; D019317:Evidence-Based Medicine; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007262:Infusions, Intravenous; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000503:physiopathology; D011655:Pulmonary Embolism / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic; D020521:Stroke / Q000188:drug therapy; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000009:adverse effects; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage / Q000009:adverse effects
D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator